Lilly Claims Zydus Broke Deal In Strattera Row

Law360, New York (May 9, 2011, 2:13 PM EDT) -- Eli Lilly & Co. slapped Zydus Pharmaceuticals USA Inc. with a patent infringement suit Thursday in New Jersey, accusing it of breaching a consent order entered in a previous case Lilly brought over attention deficit hyperactivity disorder treatment Strattera.

Lilly's complaint, filed in federal court in Newark, said Zydus' bid for approval for 10-milligram generic Strattera capsules came with a Paragraph IV certification claiming that a patent for the drug is invalid, even though Zydus stipulated that the patent was not invalid in the December 2007...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.